In order to investigate what happens in vivo in PNH patients on eculizumab, we have designed a novel experimental setting [31], whereby RBCs from PNH patients are exposed to the mild activation of complement that mimics the in vivo spontaneous activation of CAP known as C3 “tickover”. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.